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Background: A number of early features can precede
the diagnosis of Parkinson’s disease (PD).
Object ive: To test an online, evidence-based algo-
rithm to identify risk indicators of PD in the UK
population.
Methods: Participants aged 60 to 80 years without
PD completed an online survey and keyboard-tapping
task annually over 3 years, and underwent smell tests
and genotyping for glucocerebrosidase (GBA) and leu-
cine-rich repeat kinase 2 (LRRK2) mutations. Risk
scores were calculated based on the results of a sys-
tematic review of risk factors and early features of PD,
and individuals were grouped into higher (above 15th
centile), medium, and lower risk groups (below 85th
centile). Previously defined indicators of increased risk
of PD (“intermediate markers”), including smell loss,
rapid eye movement–sleep behavior disorder, and
finger-tapping speed, and incident PD were used as
outcomes. The correlation of risk scores with intermedi-
ate markers and movement of individuals between risk
groups was assessed each year and prospectively.
Exploratory Cox regression analyses with incident PD
as the dependent variable were performed.
Results : A total of 1323 participants were recruited at
baseline and >79% completed assessments each year.
Annual risk scores were correlated with intermediate
markers of PD each year and baseline scores were cor-
related with intermediate markers during follow-up (all P
values<0.001). Incident PD diagnoses during follow-up
were significantly associated with baseline risk score
(hazard ratio5 4.39, P5.045). GBA variants or G2019S
LRRK2 mutations were found in 47 participants, and the
predictive power for incident PD was improved by the
addition of genetic variants to risk scores.
Conclusions: The online PREDICT-PD algorithm is a
unique and simple method to identify indicators of PD
risk. VC 2017 The Authors. Movement Disorders pub-
lished by Wiley Periodicals, Inc. on behalf of Interna-
tional Parkinson and Movement Disorder Society.
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The prodromes of Parkinson’s disease (PD) can begin
many years before diagnosis1,2 and offer an opportunity
to identify individuals in the earlier stages of the dis-
ease.3 Studies aiming to identify patients at risk of PD
have mainly centred on individuals with a family history
of PD or asymptomatic carriers of genes associated with
PD, idiopathic anosmia, rapid eye movement–sleep
behavior disorder (RBD), or with imaging abnormalities
associated with increased risk (such as hyperechogenic-
ity on transcranial sonography and nigrostriatal deficit
on dopamine transporter imaging).4-7
These studies are limited by the rarity, representative-
ness, and/or feasibility of identifying these factors
because of cost or availability and by the large numbers
needing to be screened, given the incidence rate of PD
of approximately 200 per 100,000 person-years in
those over the age of 60 years.8 Here we report 3-year
data on a novel method to recruit and identify individu-
als with risk indicators of PD through an online screen-
ing process using an algorithm derived from a meta-
analysis of known risk and prodromal features of PD.9
Methods
Data Collection
We previously reported the methods of a study to
estimate and test risk of PD based on a systematic
review of associations of risk factors and early PD fea-
tures with a subsequent diagnosis of PD and prospec-
tive evaluation of a community-based population.9,10
In brief, participants were recruited via the study web-
site following an advertising campaign in 2011 (which
included emails to members of the Parkinson’s UK
charity). The study was approved by the Queen
Square Research Ethics Committee (reference 10/
H0716/85). Inclusion criteria at baseline included resi-
dency in the United Kingdom and age between 60 to
80 years. Exclusion criteria were preexisting and self-
reported PD, any other movement disorder, stroke,
motor neuron disease, dementia, or drug usage known
to be associated with iatrogenic parkinsonism.
The volunteers were prompted by email to return to the
website and complete the tests on a yearly basis. The sur-
vey included demographic questions and items on early
nonmotor features and risk factors for PD, including vali-
dated questionnaires, such as the Hospital Anxiety
Depression Scale and the RBD Screening Questionnaire
(RBDSQ) as well as questions that had been associated
with increased risk of PD previously in observational stud-
ies.9,11,12 Participants undertook an online keyboard-
tapping task each year, the BRadykinesia Akinesia INco-
ordination test (BRAIN test; available at www.braintapt-
est.com), which has been validated to assess upper limb
motor function in PD.13 The U.S. version of the University
of Pennsylvania Smell Identification Test (UPSIT) was
posted to them at baseline and in year 3, and the answers
were completed both online and in the smell test book-
lets.14 Each year the survey included a question on wheth-
er the participants had been given any new diagnoses, and
they were specifically asked about “Parkinson’s disease”
and/or “movement disorder.” Positive responses to these
2 diagnoses were followed up by telephone interview. For
newly diagnosed patients with PD, the telephone inter-
view was followed with a home visit and in-person clinical
examination by A.J.N. to ensure that U.K. Brain Bank
diagnostic criteria were met and to gather further infor-
mation.15 Participants lost to follow-up were defined as
those who did not complete submissions any year after
baseline. No additional participants were recruited after
the baseline year.
Genotyping
Saliva collection tubes were dispatched alongside the
smell tests to respondents of the year 3 follow-up sur-
vey. Saliva was returned by post and DNA was
extracted using standard methods. Direct Sanger
sequencing was used to genotype participants for
mutations in exons 8-11 of glucocerebrosidase (GBA)
(which contains>95% of known GBA pathogenic
mutations) and exon 41 in the leucine-rich repeat
kinase 2 (LRRK2) gene was screened for the G2019S
mutation.16 Further details of genetic analysis are pro-
vided in the supplementary material.
Risk Score Ranking and Outcomes
Early features and risk factors assessed online were
used to calculate a risk score (see supplementary mate-
rial, including Supplementary Table 1), and partici-
pants were ranked according to their risk score.
Because incident cases of PD were expected to be few
during follow-up, support for enrichment of the popu-
lation at risk of PD was tested by examining associa-
tions between risk scores and the following previously
established factors which are associated with a high
risk of PD (intermediate markers): reduced sense of
smell (assessed using the UPSIT), presence of subjec-
tive RBD (using the RBDSQ), and slowing of finger-
tapping speed (using the kinesia score [KS; number of
alternate key taps in 30 seconds] for the slower hand).
The Movement Disorder Society Task Force recently
reported an increased risk of PD in those with hypo-
smia (likelihood ratio [LR] 4.0), subjective RBD (LR
2.3), and abnormal quantitative motor testing (LR
3.5).17 These 3 intermediate markers were therefore
not included in the algorithm, but used as outcomes
to assess the performance of the algorithm.
Analyses
Annual risk estimates in all of the participants were
ranked from highest to lowest, and this ranking was used
to identify higher, middle, and lower risk groups. For
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this prospective analysis, we used centile-based cut-offs
to determine higher (>15th centile) and lower (<85th
centile) risk groups (rather than groups with fixed num-
bers) so that these groups would reduce in proportion to
the overall number of participants during follow-up.
A priori hypotheses for longitudinal follow-up were
that higher risk scores at baseline would be associated
with abnormal scores on intermediate marker scales dur-
ing follow-up (longitudinal) and that higher risk scores
each year would be associated with abnormal scores on
intermediate marker scales (cross-sectional). In an explor-
atory analysis, it was hypothesized that higher risk scores
(with and without the inclusion of odds ratios associated
with specific genetic variants), and intermediate markers
would be associated with new diagnoses of PD.
Statistical Methods
To assess reproducibility of the methods, risk scores
were calculated annually. The associations between
annual risk scores and intermediate markers that year
were examined using regression, and higher and lower
risk groups were compared for intermediate markers of
PD that year (except smell, which was tested at base-
line and year 3 only). Movement between higher, low-
er, and middle risk groups each year was also studied.
For longitudinal performance of the algorithm, the
association of baseline risk scores with intermediate out-
comes at follow-up was examined, and baseline higher
and lower risk groups were compared for intermediate
markers during follow-up. Descriptive information on
individuals with a PD diagnosis during follow-up was giv-
en, and an exploratory analysis of the association of base-
line risk scores with later incident PD was performed.
KS (tapping speed) between groups was compared using
t tests and described using means and 95% confidence
intervals (CI). UPSIT and RBDSQ scores were not normal-
ly distributed, and medians and interquartile range and
Wilcoxon rank sum tests were used. Comparisons for cate-
gorical data (defined by cut-off values for each intermedi-
ate marker) were made using Fisher’s exact test. Cut-off
values for smell loss, RBD, and tapping speed based on
the 15th centile for each intermediate marker using UPSIT,
RBDSQ, and KS were identified (scores of27,5, and
44, respectively). These were similar to those in the pub-
lished literature.12,13,18 A chi-square test for trend was
used to compare the frequency of genetic variants between
the higher, middle, and lower risk groups.
The relationships of risk scores in the entire dataset
(independent variable) with UPSIT, RBDSQ, and KS
(dependent variables) were examined using median,
linear, and Poisson regression, respectively. Explorato-
ry Cox regression was used to calculate hazard ratios
(HR) for the association between baseline risk scores
and incident PD and between baseline intermediate
markers and incident PD. The regression model was
repeated in the subset of participants for whom GBA
and LRRK2 status was known (with odds ratios asso-
ciated with genetic risk factors included in the algo-
rithm). Participants with newly diagnosed PD were
excluded from the analyses of outcomes in the years
following diagnosis. All analyses were performed using
Stata (StataCorp LP, College Station, Texas).
Results
At baseline, 1,323 eligible volunteers were recruited,
and 1,040 of the voluteers completed follow-up testing
in year 1 (79% of baseline), 939 in year 2 (90% of year
1 and 71% of baseline respondents), and 846 in year 3
(90% of year 2 and 64% of baseline). A total of 223
participants (17%) completed the baseline assessment
only. Using 15th centile risk cut-offs, there were 198
participants each in the higher and lower risk groups at
baseline, 155 in each group at year 1, 140 participants
in each group in year 2, and 125 and 126 in the higher
and lower risk groups in year 3, respectively (Fig. 1).
Baseline data are presented in Table 1 and Supplemen-
tary Table 2. Demographic and risk factor data for each
follow-up year are presented in Supplementary Table 3.
Those that continued to participate in the study were
younger than those who were lost to follow-up but
were otherwise similar (Supplementary Table 4).
Longitudinal Analysis of Baseline Risk Scores
With Outcomes Over 3 Years
Baseline risk scores were associated with significantly
higher rates of all intermediate markers of PD during
each year of follow-up (P< 0.001; Supplementary Table
5). In addition, the higher risk group had significantly
worse UPSIT, RBDSQ, and KS in all years than the
lower risk group and had a greater proportion of indi-
viduals with smell loss, RBD, and slowed finger tapping
according to predefined cut-offs in every year of follow-
up (all P 0.003 except for the association between
risk group and abnormal finger tapping in year 2
(P50.080; see Table 2 and Supplementary Table 6).
Comparison of Frequencies of Gene Variant
Carriers by Baseline Risk
Sequencing of G2019S LRRK2 mutation was success-
ful for 806 samples (98% success). Comparisons with
the reference sequence led to the detection of 2 (0.26%)
heterozygous carriers of the G2019S LRRK2mutation.
Sequencing of GBA in 826 samples (of which 192
had been screened at an earlier stage16) yielded clear
sequences for all screened exons in 800 participants
(97% success). Comparisons with the reference
sequence led to the detection of 45 carriers of GBA
variant alleles of which 23 were E326K (20 heterozy-
gous and 3 homozygous), 12 T369M (11 heterozygous
and 1 homozygous), 8 N370S, 1 R463C, and 1
RecNcil (recombinant allele associating L444P,
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A456P, and V460V). The overall frequency of GBA
variants in the screened cohort was 5.45%.
The frequency of GBA carriers was 6.8% (10/146),
5.4% (28/516), and 5.0% (7/138) in the higher,
middle, and lower risk groups, respectively. Compar-
ing these frequencies using the chi-square for trend did
not provide evidence of association by risk group
(P50.51).
TABLE 1. Patient characteristics at baseline
All Higher risk Lower risk
Age 66.2 (63.5-70.5) 70.2 (67.1-74.7) 63 (61.4-64.6)
Female 806 (60.9%) 42 (21.2%) 170 (85.9%)
Current smoker 51 (3.9%) 3 (1.5%) 28 (14.1%)
Past smoker 541 (40.9%) 87 (43.9%) 88 (44.4%)
Coffee 1187 (89.7%) 173 (87.4%) 194 (98%)
Hypertension 348 (26.3%) 59 (29.8%) 75 (37.9%)
NSAID use 83 (6.3%) 6 (3%) 19 (9.6%)
CCB use 155 (11.7%) 30 (15.2%) 25 (12.6%)
Alcohol 1143 (86.4%) 179 (90.4%) 177 (89.4%)
1st degree relative 208 (15.7%) 74 (37.4%) 1 (0.5%)
Constipation 215 (16.3%) 73 (36.9%) 1 (0.5%)
Head injury 327 (24.7%) 86 (43.4%) 11 (5.6%)
Beta blocker use 103 (7.8%) 30 (15.2%) 15 (7.6%)
Depression/anxietya 159 (12%) 37 (18.7%) 9 (4.5%)
Erectile dysfunction 180 (34.8%) 132 (84.6%) 0 (0%)
NSAID, nonsteroidal anti-inflammatory drugs; CCB, calcium channel blockers.
aHospital Anxiety Depression Scale score 11 (moderate); higher and lower risk are defined by the 15th and 85th centiles of risk scores, respectively.
FIG. 1. Participant numbers, dropout rates, and new diagnoses of PD. Note that some participants completed follow-up assessments at year 2 but
not year 1 (46 [3.5%]), at year 3 but not years 1 and 2 (14 [1.1%]), or at year 1 and 3 but not year 2 (42 [4.0%]). [Color figure can be viewed at
wileyonlinelibrary.com]
N O Y C E E T A L
222 Movement Disorders, Vol. 32, No. 2, 2017
Cross-Sectional Association of Risk Scores
With Outcomes Each Year
Risk scores across the whole group were strongly
associated with intermediate markers each year (all P
values<0.001). Higher and lower risk groups differed
significantly in median UPSIT, RBDSQ, and mean KS
score in all years of follow-up (P values all0.001;
see Table 3 and Supplementary Table 7). In addition,
the higher risk group had a greater proportion of indi-
viduals with smell loss, RBD, and slowed finger tap-
ping according to predefined cut-offs than the lower
risk group each year (all P< 0.05).
Movement Between Groups
The majority of individuals remained in the same
risk group (higher, middle, lower). However, annual
changes of risk led to the movement of some partici-
pants between groups (Supplementary Figure).
Between baseline and year 1, approximately 20% of
both the higher and lower risk group moved to the
middle risk group, in year 2, 26% and 15%, respec-
tively, moved groups, and similar changes were
observed in year 3. No participant moved from the
higher to the lower risk group in any year, and 1
(0.1% of the cohort) from the lower to the higher risk
group in year 1 only.
Incident Diagnosis of PD During Follow-Up
At year 1, 3 patients had been newly diagnosed with
PD. Another participant was diagnosed in year 2, and
3 more in year 3. Of the participants with newly diag-
nosed PD at year 1, all 3 were in the higher risk
group, and 2 had also been in the higher risk group at
baseline. The participant diagnosed at year 2 was in
the higher risk group at baseline, year 1, and year 2
year of follow-up. Of the 3 participants diagnosed by
year 3, all were in the middle risk group at baseline; 1
was in the higher risk group in the year prior to diag-
nosis, and there were marked increases in the rank of
the risk estimates prior to diagnosis for the other 2
participants. On clinical examination, all patients sat-
isfied the U.K. Brain Bank criteria for PD.15 Further
details regarding rankings, intermediate markers,
motor features, treatment, UPDRS motor scores,
genetic information, and dopamine transporter imag-
ing (where available) are provided in Supplementary
Tables 8 and 9. There was substantial heterogeneity in
the occurrence of intermediate markers in these indi-
viduals, with hyposmia in 4, reduced tapping speed in
5, and 4 reporting RBD symptoms according to prede-
fined cut-offs.
The incidence of independently diagnosed PD in
subjects that had been in the higher risk group during
3 years of follow-up was 1.6% per year (6 partici-
pants of 125 higher risk) and 0.2% across the whole
cohort. Exploratory Cox regression analysis using inci-
dent PD over 3 years as the outcome showed an asso-
ciation with baseline risk estimate (HR 4.39; 95% CI
1.03-18.68; P50.045). In the repeat analysis, restrict-
ed to participants for whom GBA and LRRK2 status
was known (789 participants), conservative odds
ratios for the presence of variants associated with the
risk of PD were included in the algorithm (see Supple-
mentary Table 10). In this smaller sample, the associa-
tion between baseline risk and incident PD was overall
weaker (HR 3.44; 95% CI 0.85-13.99; P5 .084; see
Table 4), but the addition of GBA and LRRK2 var-
iants in the algorithm improved the strength of associ-
ation between baseline risk and incident PD (HR 4.22;
TABLE 2. Longitudinal associations of baseline risk scores
with UPSIT, RBDSQ, and tapping speed at year 3
Higher risk Lower risk P valuea
UPSIT score
n 130 132
Median (IQR) 30 (26-33) 33 (30-35) <.001
<27 (%) 40 (31) 15 (11) <.001
RBDSQ score
n 140 139
Median (IQR) 2 (1-4) 1 (0-3) <.001
>5 (%) 33 (24) 10 (7) <.001
KS score
n 135 130
Mean (95% CI) 51.3 (49.5-53.2) 55.5 (53.6-57.4) .001
<44 (%) 40 (30) 17 (13) .002
IQR, interquartile range; CI,confidence interval; KS, kinesia score for the
worst hand; RBDSQ, rapid eye movement sleep behavior disorder screen-
ing questionnaire; UPSIT, University of Pennsylvania smell identification
test.
aP value from comparative analysis between higher and lower risk groups
using Wilcoxon Rank Sum test for UPSIT and RBDSQ, t test for KS for con-
tinuous data, and Fisher’s exact test for categorical data.
TABLE 3. Cross-sectional association of year 3 risk scores
with UPSIT, RBDSQ, and tapping speed at year 3
Higher risk Lower risk P valuea
UPSIT score
n 117 118
Median (IQR) 30 (26-33) 33 (30-35) <.001
<27 (%) 39 (33) 14 (12) <.001
RBDSQ score
n 125 126
Median (IQR) 3 (1-5) 1 (0-3) <.001
>5 (%) 34 (27) 5 (4) <.001
KS score
n 123 119
Mean (95% CI) 50.9 (48.9-52.9) 55.5 (53.4-57.6) .001
<44 (%) 36 (29) 19 (16) .015
IQR, interquartile range; CI, confidence interval; KS, kinesia score for the
worst hand; RBDSQ, rapid eye movement sleep behavior disorder screen-
ing questionnaire; UPSIT, University of Pennsylvania smell identification
test.
aP value from comparative analysis between higher and lower risk groups
using Wilcoxon Rank Sum test for UPSIT and RBDSQ, t test for KS for con-
tinuous data, and Fisher’s exact test for categorical data.
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95% CI 1.21-14.73; P5 .024). Of the intermediate
markers, baseline finger tapping was associated with
incident PD at 3 years (HR 0.91; 95% CI 0.84-0.98),
but not RBDSQ. An association with baseline UPSIT
scores could not be calculated because of small num-
bers (see Supplementary Table 8).
Discussion
The online assessment of established risk factors and
early features of PD has the potential to identify indi-
viduals with increased risk of PD from the general
population. Our results suggest that the approach is
effective and reproducible in identifying a group of
individuals with increased risk markers of PD during a
period of 3 years, and suggest enrichment of the popu-
lation for incident PD. In this cohort, risk scores
defined by the PREDICT-PD algorithm at baseline and
during each year of follow-up were significantly asso-
ciated with intermediate markers of PD (smell loss,
RBD, and slowed tapping speed) at follow-up. In
addition, despite some movement between groups
each year, the higher risk group had an increased rate
of intermediate markers of PD during follow up, and
higher baseline risk scores were associated with
increased rate of incident PD. These results overall
suggest that risk stratification using these methods is
feasible. Although only a small number of individuals
have been independently diagnosed with PD during
follow-up so far, the overall incidence of 0.2% is con-
sistent with expected incidence rate in the age group
of 60 to 80 years from the general population (1-3 per
1000 per year8) and supports the representativeness of
our sample. The higher risk group in this study was
enriched approximately 5-fold, supporting the overall
findings of the study that the online algorithm can
identify increased risk of PD in the population.
A total of 7 cases after a large population screening
and follow-up for 3 years is still a low number, but
this is expected given the incidence of PD. However,
this Internet-based approach may be useful for
population screening because it can easily be scaled
upward. It will allow larger numbers of PD cases that
represent the spectrum of the disease to be identified
rather than what would be possible from cohorts of
carriers of specific risk factors. It should be empha-
sized, however, that inclusion in the higher risk group
alone is not predictive of subsequent PD diagnosis in
individual participants.
Some movement was observed between higher, mid-
dle, and lower risk groups each year, as would be
expected given the subjective nature of online survey-
ing and the potential for symptoms to vary over time
(eg, mood and bowel habit). Measures were taken to
increase concordance through detailed instructions
and personal communications to discount statistically
and clinically improbable data (see supplementary
material), but some inaccuracy may have been intro-
duced through these methods. However, this would be
more likely to increase the noise and reduce the signif-
icance of findings rather than lead to differential mis-
classification. The maximum percentage change within
a group was seen in the higher risk participants
between years 1 and 2 (26% moving to the middle
risk group), but in general changes were limited to less
than 20%, and no patient in the higher risk group
switched to the lower risk group. Overall, stratifica-
tion may therefore be most informative if repeated.
The inclusion of genetic variants in the algorithm
improved the prediction of incident PD over the risk
algorithm alone. The frequency of GBA variants was
5.45%, which is slightly higher than that of healthy con-
trols (4.24%) in other studies19; but a frequency of
0.26% was found for the G2019S LRRK2 mutation,
similar to previous observations.20 The distribution of
mutation carriers across the baseline risk groups showed
a slight gradient in direction of the higher risk group, but
it was not statistically significant and was in contrast to
that observed in preliminary subgroup testing.16 The pre-
viously observed finding may have resulted from under-
sampling in the middle risk group, giving rise to low
statistical power and the potential for false positives.
However, when GBA and LRRK2 effects were included
in the model with the risk algorithm, the strength of
association increased between baseline risk and incident
PD at 3 years of follow-up. Of the baseline intermediate
markers of PD, only finger tapping at baseline was asso-
ciated with incident PD at 3 years. This is likely because
subjective RBD symptoms only occurred in 2 of the 7
incident cases, and UPSIT scores from baseline were only
available for 3 of the 7 incident cases. Overall the num-
ber of converters currently is too small to draw robust
conclusions, but these follow-up results are encouraging.
The clustering of early nonmotor features has been
studied in the PARS (Parkinson Associated Risk Study)
and T€ubinger evaluation of Risk factors for the Early
detection of NeuroDegeneration (TREND) studies, but
TABLE 4. Exploratory Cox regression analysis of associa-
tion between baseline risk (with and without genetic var-
iants), and baseline intermediate markers, with incident PD
at 3 years of follow-up
HR (95% CI) P value
Log risk without variants 3.44 (0.85-13.99) .084
Log risk with variants 4.22 (1.21-14.73) .024
UPSITa – –
RBDSQ 1.21 (0.92-1.59) .177
KS 0.91 (0.84-0.98) .012
HR, hazard ratio; CI, confidence interval; KS, kinesia score for the worst
hand; RBDSQ, rapid eye movement sleep behavior disorder screening
questionnaire; UPSIT, University of Pennsylvania smell identification test.
aBaseline UPSIT data were only available on 3 of the 7 incident cases.
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the co-occurrence of features still requires further clar-
ification. In PARS, participants with hyposmia were
more likely to report altered mood (anxiety and
depression), RBD symptoms, and constipation.18 In
those who went on to have dopamine transporter
imaging, hyposmia, male gender, and constipation
combined effectively to predict dopaminergic deficit.5
In the TREND study, which recruited based on the
presence of 1 or more of depression, RBD, and anos-
mia, the clustering of prodromal features was also
observed.21
Cohorts that follow high-risk groups, such as those
with genetic mutations or RBD, provide important
insights into the long-term prodrome of PD, may pro-
vide platforms for biomarker studies and treatment
trials, and guide research in this area. However, the
strategies that measure multiple prodromal features
and generate composite exposure information will be
more likely to yield the greatest sensitivity and specif-
icity for future diagnosis than individual markers. A
recent development in this area is the new Criteria for
Prodromal Parkinson’s Disease from the MDS Task
Force.17 When compared with the aforementioned
studies, PREDICT-PD has recruited participants with
a much wider spectrum of risk for PD than those
recruiting based on selected prodromal markers. Such
wider recruitment might offer a better representation
of the spectrum of PD, and acknowledge that not all
that go on to be diagnosed with PD may not have
those specific markers.
Limitations
We acknowledge the selection bias that may have
occurred in the recruitment of participants, including
a mailshot through Parkinson’s UK, the resulting high
frequency of participants with a family history of PD,
and therefore a small excess in the prevalence of GBA
variants. However, we did not use family history as
an entry criterion, and the proportion with a positive
family history was lower than in other landmark stud-
ies such as TREND and PARS.5,21 There was also an
overall drop out of 17% of participants who only
completed the baseline assessment but no follow-up
assessments. This may also have introduced selection
bias, although there were no differences between those
with or without follow-up, meaning that bias as a
result of loss to follow-up was less likely. Notably, the
greatest loss to follow-up was between baseline and
year 1 follow-up because the study was funded to run
as a cross-sectional study before further funding
enabled the cohort to be followed over time. Informa-
tion relating to a new diagnosis of PD relied on self-
report and the retention of participants within the
study. Reporting bias or differential loss to follow-up
could therefore have played a role in the observed
results, but it is reassuring that there were no obvious
differences between the participants who continued to
participate and those who dropped-out, reducing the
probability of such bias. Although two intermediate
markers were measured objectively, a potential limita-
tion to our approach was the use a subjective ques-
tionnaire for one intermediate marker, the RBDSQ.22
The identification of only 7 individuals over 3 years
with the current algorithm is a limitation for imple-
mentation. However, the ease of application makes
enlargement of the cohort and validation in other
cohorts a possibility. Future work is required to refine
the algorithm, identify individual components with the
greatest contribution, and reduce movement between
groups. Combining the current algorithm with a more
extensive genetic risk scoring approach may signifi-
cantly improve predictive capabilities.23 Longer
follow-up with in-depth study (including imaging and
eventual postmortem examination) will identify a
greater number of participants who have developed
PD to allow further characterization of the higher and
lower risk groups and refinement of the algorithm.
Finally, our results will need to be replicated in inde-
pendent samples in different populations.
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